Primer: Ascletis Pharma (1672 HK) - May 2026
Ascletis is undergoing a critical strategic pivot from its legacy Hepatitis C (HCV) franchise, which has seen revenues collapse, to a high-risk,...
88 Views
𝛼SK or SearchENTITY
Ascletis Pharma (1672 HK)
Ascletis Pharma (1672 HK)
96
Analysis
Health Care • China
Ascletis Pharma is a fully integrated biotechnology company focused on the research, development, production, marketing, and sale of innovative pharmaceutical products. The company's marketed products include Ritonavir tablets, GANOVO®, and ASCLEVIR® for Hepatitis C, and it has a robust pipeline primarily in metabolic diseases, viral diseases, and oncology. Ascletis Pharma is headquartered in Hangzhou, China, and was founded in 2011.
morex